# EcPLA

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/EcPLA
> Markdown URL: https://mediated.wiki/source/EcPLA.md
> Source: https://en.wikipedia.org/wiki/EcPLA
> Source revision: 1339774515
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

{{Short description|Chemical compound}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Drugbox
| image = ECPLA.svg
| image_class = skin-invert-image
| width = 165px
| image2 = EcPLA 3D.png
| image_class2 = bg-transparent
| width2 = 225px

<!-- Clinical data -->
| tradename = 
| routes_of_administration = [Oral](/source/Oral_administration)
| class = [Serotonin receptor modulator](/source/Serotonin_receptor_modulator); [Serotonin 5-HT<sub>2A</sub> receptor agonist](/source/Serotonin_5-HT2A_receptor_agonist); [Serotonergic psychedelic](/source/Serotonergic_psychedelic); [Hallucinogen](/source/Hallucinogen)

<!-- Legal status -->
| legal_AU =  
| legal_CA =  
| legal_DE = NpSG
| legal_UK = PSA
| legal_US =
| legal_US_comment = 
| legal_status = Illegal in France<ref>{{cite web | title = Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants | date = 20 May 2021 | url = https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000043523554 | website = www.legifrance.gouv.fr | lang = fr }}</ref>

<!-- Identifiers -->
| CAS_number = 2349367-50-4
| PubChem = 163184957
| ChemSpiderID = 129395457
| synonyms = ECYPLA; ''N''-Ethyl-''N''-cyclopropyllysergamide; Lysergic acid ethylcyclopropylamide; LAEcP

<!-- Chemical data -->
| IUPAC_name = (6a''R'',9''R'')-''N''-cyclopropyl-''N''-ethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-''fg'']quinoline-9-carboxamide
| C=21 | H=25 | N=3 | O=1 
| SMILES = CCN(C1CC1)C(=O)[C@@H]3C=C2c4cccc5ncc(C[C@H]2N(C)C3)c45
| StdInChI = 1S/C21H25N3O/c1-3-24(15-7-8-15)21(25)14-9-17-16-5-4-6-18-20(16)13(11-22-18)10-19(17)23(2)12-14/h4-6,9,11,14-15,19,22H,3,7-8,10,12H2,1-2H3/t14-,19-/m1/s1
| StdInChIKey = UNUJKEQFYPYXBK-AUUYWEPGSA-N
}}

'''EcPLA''', also known as '''''N''-ethyl-''N''-cyclopropyllysergamide''' or as '''lysergic acid ethylcyclopropylamide''' ('''LAEcP'''), is a [psychedelic drug](/source/psychedelic_drug) of the [lysergamide](/source/substituted_lysergamide) family related to [lysergic acid diethylamide](/source/lysergic_acid_diethylamide) (LSD).<ref name="KavanaghWestphalStratford2020">{{Cite journal | vauthors = Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, Halberstadt AL, Brandt SD | title = Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ) | journal = Drug Testing and Analysis | volume = 12 | issue = 10 | pages = 1514–1521 | date = 2020 | pmid = 32803833 | pmc = 9191644 | doi = 10.1002/dta.2911 | language = en | issn = 1942-7611 }}</ref><ref name="HalberstadtKleinChatha2019" /><ref name="Aipsin">{{cite web | title=ECPLA | website=АИПСИН | url=https://aipsin.com/newsubstance/831/ | language=ru | access-date=1 January 2026}}</ref> It is an [isomer](/source/isomer) of [LSZ](/source/LSZ_(drug)) and is closely related to other [amide](/source/amide)-substituted lysergamides like [MiPLA](/source/MiPLA).<ref name="HalberstadtKleinChatha2019" /><ref name="KavanaghWestphalStratford2020" /><ref name="WachełkoNowakTusiewicz2025" /><ref name="Aipsin" /> The drug has been encountered as a novel [designer drug](/source/designer_drug).<ref name="Aipsin" />

==Use and effects==
EcPLA produces [psychedelic](/source/psychedelic_drug) effects in humans.<ref name="Aipsin" />

==Interactions==
{{See also|Psychedelic drug#Interactions|Trip killer#Serotonergic psychedelic antidotes}}

==Pharmacology==
===Pharmacodynamics===
EcPLA has been found to interact with [serotonin receptor](/source/serotonin_receptor)s and [dopamine receptor](/source/dopamine_receptor)s, among other [target](/source/biological_target)s. It is a [high potency](/source/potency_(pharmacology)) [agonist](/source/agonist) of the [serotonin](/source/serotonin) receptors, with its highest binding affinities at the [5-HT{{sub|1A}}](/source/5-HT1A_receptor) ({{mvar|K{{sub|i}}}} = {{val|3.2|u=nM}}), [5-HT{{sub|2B}}](/source/5-HT2B_receptor) ({{mvar|K{{sub|i}}}} = {{val|5.3|u=nM}}), and [5-HT{{sub|5A}}](/source/5-HT5A_receptor) ({{mvar|K{{sub|i}}}} = {{val|8.6|u=nM}}) subtypes. Its  [5-HT{{sub|2A}}](/source/5-HT2A_receptor) affinity is equivalent to that of [LSD](/source/LSD), while the affinity to [5-HT{{sub|2C}} receptor](/source/5-HT2C_receptor)s is 3 times lower than LSD. It shares much of its binding profile with LSD, but does not bind to [β1](/source/Beta-1_receptor) or [β2](/source/Beta-2_receptor) [adrenergic](/source/adrenergic_receptor) receptors as LSD does.<ref name="HalberstadtKleinChatha2019">{{cite journal | vauthors = Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, Nichols DE, Brandt SD | title = Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) | journal = Psychopharmacology | volume = 236 | issue = 2 | pages = 799–808 | date = February 2019 | pmid = 30298278 | pmc = 6848745 | doi = 10.1007/s00213-018-5117-z }}</ref>

The drug produces the [head-twitch response](/source/head-twitch_response), a behavioral proxy of [psychedelic](/source/psychedelic_drug) effects, in rodents. It has about 40% of the potency of LSD in this regard.<ref name="HalberstadtKleinChatha2019"/>

===Pharmacokinetics===
The ''[in-vitro](/source/in-vitro)'' [metabolism](/source/drug_metabolism) of EcPLA has been studied.<ref name="WagmannRichterKehl2019">{{cite journal | vauthors = Wagmann L, Richter LH, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR | title = In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures | journal = Analytical and Bioanalytical Chemistry | volume = 411 | issue = 19 | pages = 4751–4763 | date = July 2019 | pmid = 30617391 | doi = 10.1007/s00216-018-1558-9 | s2cid = 58615418 | url = http://researchonline.ljmu.ac.uk/id/eprint/9841/13/ABC-01967-2018_02_accepted.pdf }}</ref>

==Chemistry==
===Analogues===
[Analogue](/source/Structural_analog)s of EcPLA include [MiPLA](/source/methylisopropyllysergamide), [LAMPA](/source/methylpropyllysergamide) (MPLA), [EPLA](/source/ethylpropyllysergamide), [EiPLA](/source/ethylisopropyllysergamide), [ETFELA](/source/ethyltrifluoroethyllysergamide), and [LSZ](/source/LSZ_(drug)), among others.<ref name="WachełkoNowakTusiewicz2025">{{cite journal | vauthors = Wachełko O, Nowak K, Tusiewicz K, Zawadzki M, Szpot P | title = A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies | journal = Analyst | volume = 150 | issue = 2 | pages = 290–308 | date = January 2025 | pmid = 39636448 | doi = 10.1039/d4an01361a | url = }}</ref><ref name="HalberstadtKleinChatha2019" /><ref name="KavanaghWestphalStratford2020" />

==History==
EcPLA was first described in the [scientific literature](/source/scientific_literature) by a team that included [Adam Halberstadt](/source/Adam_Halberstadt), [Alexander Stratford](/source/Alexander_Stratford), [Jason Wallach](/source/Jason_Wallach), and [David E. Nichols](/source/David_E._Nichols) in 2019.<ref name="HalberstadtKleinChatha2019" /> It was developed by [Lizard Labs](/source/Lizard_Labs).{{Citation needed|date=October 2025}} The drug was encountered online as a novel [designer drug](/source/designer_drug) in around 2020 and became more widely available in early 2022.<ref name="Aipsin" />

== See also ==
* [Substituted lysergamide](/source/Substituted_lysergamide)
* [Lizard Labs](/source/Lizard_Labs)

== References ==
{{Reflist}}

==External links==
* [https://isomerdesign.com/pihkal/explore/2843 ECPLA - Isomer Design]

{{Psychedelics}}
{{Serotonin receptor modulators}}
{{Dopamine receptor modulators}}
{{Ergolines}}

Category:5-HT2A agonists
Category:5-HT2B agonists
Category:5-HT2C agonists
Category:Carboxamides
Category:Cyclopropyl compounds
Category:Designer drugs
Category:Dopamine receptor modulators
Category:Ethyl compounds
Category:Lizard Labs
Category:Methyl compounds
Category:Psychedelic lysergamides
Category:Serotonin receptor modulators

---
Adapted from the Wikipedia article [EcPLA](https://en.wikipedia.org/wiki/EcPLA) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/EcPLA?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.
